» Articles » PMID: 30094590

Heparin: Role in Protein Purification and Substitution with Animal-component Free Material

Overview
Date 2018 Aug 11
PMID 30094590
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Heparin is a highly sulfated polysaccharide which belongs to the family of glycosaminoglycans. It is involved in various important biological activities. The major biological purpose is the inhibition of the coagulation cascade to maintain the blood flow in the vasculature. These properties are employed in several therapeutic drugs. Heparin's activities are associated with its interaction to various proteins. To date, the structural heparin-protein interactions are not completely understood. This review gives a general overview of specific patterns and functional groups which are involved in the heparin-protein binding. An understanding of the heparin-protein interactions at the molecular level is not only advantageous in the therapeutic application but also in biotechnological application of heparin for downstreaming. This review focuses on the heparin affinity chromatography. Diverse recombinant proteins can be successfully purified by this method. While effective, it is disadvantageous that heparin is an animal-derived material. Animal-based components carry the risk of contamination. Therefore, they are liable to strict quality controls and the validation of effective good manufacturing practice (GMP) implementation. Hence, adequate alternatives to animal-derived components are needed. This review examines strategies to avoid these disadvantages. Thereby, alternatives for the provision of heparin such as chemical synthesized heparin, chemoenzymatic heparin, and bioengineered heparin are discussed. Moreover, the usage of other chromatographic systems mimetic the heparin effect is reviewed.

Citing Articles

Butyrate Increases Heparin Synthesis and Storage in Human Mast Cells.

Alam S, Yan Z, Verma N, Unsworth L, Kulka M Cells. 2024; 13(15.

PMID: 39120272 PMC: 11311861. DOI: 10.3390/cells13151241.


The effect of different dose of heparin using in peripheral arteriovenous synchronous blood exchange transfusion for neonatal hyperbilirubinemia.

Guan X, Guo J, Xiao D, Wu Z J Med Biochem. 2024; 43(1):126-132.

PMID: 38496024 PMC: 10943456. DOI: 10.5937/jomb0-45223.


A Novel Tandem-Tag Purification Strategy for Challenging Disordered Proteins.

Meszaros A, Muwonge K, Janvier S, Ahmed J, Tompa P Biomolecules. 2022; 12(11).

PMID: 36358915 PMC: 9687501. DOI: 10.3390/biom12111566.


Enhanced Production of ECM Proteins for Pharmaceutical Applications Using Mammalian Cells and Sodium Heparin Supplementation.

Garcia-Pardo J, Montane S, Aviles F, Tanco S, Lorenzo J Pharmaceutics. 2022; 14(10).

PMID: 36297573 PMC: 9609459. DOI: 10.3390/pharmaceutics14102138.


Whether heparin causes hemolysis: an in silico and in vitro study.

Surender , Chowdhary S, Kumar D, Kaur S, Bhattacharyya R, Banerjee D Indian J Thorac Cardiovasc Surg. 2022; 38(5):566-569.

PMID: 36050977 PMC: 9424453. DOI: 10.1007/s12055-022-01340-3.


References
1.
Torrent M, Nogues M, Andreu D, Boix E . The "CPC clip motif": a conserved structural signature for heparin-binding proteins. PLoS One. 2012; 7(8):e42692. PMC: 3412806. DOI: 10.1371/journal.pone.0042692. View

2.
Robinson C, Mulloy B, Gallagher J, Stringer S . VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem. 2005; 281(3):1731-40. DOI: 10.1074/jbc.M510760200. View

3.
Handel T, Johnson Z, Crown S, Lau E, Proudfoot A . Regulation of protein function by glycosaminoglycans--as exemplified by chemokines. Annu Rev Biochem. 2005; 74:385-410. DOI: 10.1146/annurev.biochem.72.121801.161747. View

4.
McLean J . The discovery of heparin. Circulation. 1959; 19(1):75-8. DOI: 10.1161/01.cir.19.1.75. View

5.
Masuko S, Linhardt R . Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics. Future Med Chem. 2012; 4(3):289-96. PMC: 3320513. DOI: 10.4155/fmc.11.185. View